{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:43:50Z","timestamp":1778589830750,"version":"3.51.4"},"reference-count":216,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.pharmthera.2020.107626","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T22:28:22Z","timestamp":1594420102000},"page":"107626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Novel therapeutics for portal hypertension and fibrosis in chronic liver disease"],"prefix":"10.1016","volume":"215","author":[{"given":"Sergi","family":"Guix\u00e9-Muntet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Peng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Fen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Gracia-Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0005","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: A randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107626_bb0010","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1053\/jhep.2002.33469","article-title":"Somatostatin and analogues in portal hypertension","volume":"35","author":"Abraldes","year":"2002","journal-title":"Hepatology. W.B. Saunders"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107626_bb0015","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","article-title":"Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats","volume":"46","author":"Abraldes","year":"2007","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0020","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0025","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2007.01191.x","article-title":"Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: A meta-analysis","volume":"102","author":"Albillos","year":"2007","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0168-8278(94)80142-8","article-title":"Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension","volume":"21","author":"Albillos","year":"1994","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0035","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00004836-200609000-00018","article-title":"Autoimmune hepatitis triggered by statins","author":"Alla","year":"2006","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0040","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"Journal of Hepatology. Elsevier B.V"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0045","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jhep.2019.07.002","article-title":"News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document","author":"Angeli","year":"2019","journal-title":"Journal of Hepatology. Elsevier B.V"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12072-017-9798-x","article-title":"Gut\u2013liver axis, cirrhosis and portal hypertension: the chicken and the egg","volume":"12","author":"Arab","year":"2018","journal-title":"Hepatology International, Springer"},{"issue":"S1","key":"10.1016\/j.pharmthera.2020.107626_bb0055","first-page":"1","article-title":"The Pan-PPAR Agonist Lanifibranor Improves Portal Hypertension And Hepatic Fibrosis In Experimental Advanced Chronic Liver Disease","volume":"70","author":"Aristu","year":"2019","journal-title":"Hepatology. NLM (Medline)"},{"issue":"10019","key":"10.1016\/j.pharmthera.2020.107626_bb0060","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","author":"Asrani","year":"2019","journal-title":"Journal of Hepatology. Elsevier B.V"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb0070","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2-\/- (Abcb4-\/-) mouse cholangiopathy model by promoting biliary HCO\u2212\u2083 output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0075","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jhep.2020.01.017","article-title":"Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis","author":"Bajaj","year":"2020","journal-title":"Journal of Hepatology. Elsevier B.V"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0080","doi-asserted-by":"crossref","first-page":"17900","DOI":"10.1038\/s41598-017-18094-3","article-title":"Post-Transcriptional Regulation of Hepatic DDAH1 with TNF Blockade Leads to Improved eNOS Function and Reduced Portal Pressure in Cirrhotic Rats","volume":"7","author":"Balasubramanian","year":"2017","journal-title":"Scientific Reports. Nature Publishing Group"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0085","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/jgh.13200","article-title":"A short history of portal hypertension and of its management","author":"Balducci","year":"2016","journal-title":"Journal of Gastroenterology and Hepatology (Australia). Blackwell Publishing"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.510300124","article-title":"Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1- adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis","volume":"30","author":"Ba\u00f1ares","year":"1999","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107626_bb0095","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/apt.14243","article-title":"Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study","volume":"46","author":"Bang","year":"2017","journal-title":"Alimentary Pharmacology and Therapeutics. Blackwell Publishing Ltd"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107626_bb0100","first-page":"1071","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"New England Journal of Medicine. Massachussetts Medical Society"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107626_bb0105","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0016-5085(00)70368-4","article-title":"Angiotensin II induces contraction and proliferation of human hepatic stellate cells","volume":"118","author":"Bataller","year":"2000","journal-title":"Gastroenterology. W.B. Saunders"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102516","article-title":"Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis","author":"Bazwinsky-Wutschke","year":"2019","journal-title":"International Journal of Molecular Sciences. NLM (Medline)."},{"key":"10.1016\/j.pharmthera.2020.107626_bb0115","doi-asserted-by":"crossref","unstructured":"Berzigotti, A., Albillos, A., Villanueva, C., Genesca, J., Ardevol, A., Augustin, S., et al. (2017) \u2018Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study\u2019, Hepatology. CIBERehd, Instituto de Salud Carlos III, Madrid, Spain. Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain. Swiss Liver Center, Hepatology, University Clinic for Visceral Surgery and Medicine, I, Institut, 65, 1293\u20131305.","DOI":"10.1002\/hep.28992"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cld.2013.12.003","article-title":"Pharmacologic management of portal hypertension","author":"Berzigotti","year":"2014","journal-title":"Clinics in Liver Disease. W.B. Saunders"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0125","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1124\/jpet.104.079616","article-title":"Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms","volume":"313","author":"Biecker","year":"2005","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1478-3231.2008.01664.x","article-title":"Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension","volume":"28","author":"Biecker","year":"2008","journal-title":"Liver International"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: A proof-of-concept study","volume":"30","author":"Bishnu","year":"2018","journal-title":"European Journal of Gastroenterology and Hepatology. Lippincott Williams and Wilkins"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0140","first-page":"173","article-title":"Hepatotoxicity of statins and other lipid-lowering agents","author":"Bj\u00f6rnsson","year":"2017","journal-title":"Liver International. Blackwell Publishing Ltd"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107626_bb0145","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/hep.23689","article-title":"Carvedilol for portal hypertension in patients with cirrhosis","volume":"51","author":"Bosch","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0150","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nrgastro.2015.78","article-title":"Therapy: Statins and liver disease: From concern to \u201cwonder\u201d drugs?","author":"Bosch","year":"2015","journal-title":"Nature Reviews Gastroenterology and Hepatology. Nature Publishing Group"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0155","first-page":"952","article-title":"Prevention of variceal rebleeding","author":"Bosch","year":"2003","journal-title":"Lancet. Elsevier Limited"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0160","first-page":"953","article-title":"Cirrhosis as new indication for statins","volume":"69","author":"Bosch","year":"2020","journal-title":"Gut. BMJ Publishing Group"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0165","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jhep.2015.01.003","article-title":"Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments","volume":"62","author":"Bosch","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0170","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/0016-5085(81)90014-7","article-title":"Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin","volume":"80","author":"Bosch","year":"1981","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107626_bb0175","article-title":"A nutraceutical rich in docosahexaenoic acid improves portal hypertension in a preclinical model of advanced chronic liver disease","volume":"11","author":"Boyer-Diaz","year":"2019","journal-title":"Nutrients. MDPI AG"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0180","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cld.2019.06.004","article-title":"Pharmacologic Management of Portal Hypertension","author":"Bunchorntavakul","year":"2019","journal-title":"Clinics in Liver Disease. W.B. Saunders"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0185","first-page":"23","article-title":"Early administration of vapreotide for variceal bleeding in patients with cirrhosis. French Club for the Study of Portal Hypertension","volume":"344","author":"Cales","year":"2001","journal-title":"N.Engl.J Med. Services d\u2019Hepato-Gastoenterologie, Centres Hospitaliers of Angers, France"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107626_bb0190","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2337\/dc12-2012","article-title":"Dual peroxisome proliferator-activated receptor \u03b1\/\u03b4 agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects","volume":"36","author":"Cariou","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0195","first-page":"25","article-title":"Effects of angiotensin-(1\u20137) and angiotensin II on vascular tone in human cirrhotic splanchnic vessels","volume":"108","author":"Casey","year":"2018","journal-title":"Peptides. Elsevier Inc."},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb0200","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2015.12.003","article-title":"Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats","volume":"64","author":"Cerini","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0205","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology. W.B. Saunders"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0210","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with Elevated Liver Enzymes Are Not at Higher Risk for Statin Hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology. W.B. Saunders"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0215","first-page":"896","article-title":"Statins decrease the risk of decompensation in hepatitis B virus\u2013 and hepatitis C virus\u2013related cirrhosis: A population-based study","volume":"66","author":"Chang","year":"2017","journal-title":"Hepatology. John Wiley and Sons Inc."},{"key":"10.1016\/j.pharmthera.2020.107626_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107477","article-title":"The therapeutic potential of second and third generation CB1R antagonists","author":"Cinar","year":"2020","journal-title":"Pharmacology and Therapeutics. Elsevier Inc"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0225","first-page":"106","article-title":"Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: A double-blind hemodynamic investigation","volume":"22","author":"Cirera","year":"1995","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0230","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/hep.26995","article-title":"Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats","volume":"60","author":"Coch","year":"2014","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0235","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"Journal of Hepatology. Elsevier B.V"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0240","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3945\/ajcn.112.040469","article-title":"Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial","volume":"96","author":"De Gottardi","year":"2012","journal-title":"The American Journal of Clinical Nutrition"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0245","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1038\/s41598-017-02866-y","article-title":"Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies","volume":"7","author":"De Mesquita","year":"2017","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0250","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3748\/wjg.v24.i3.438","article-title":"Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up","volume":"24","author":"Deibert","year":"2018","journal-title":"World Journal of Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0255","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2036.2006.02735.x","article-title":"Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study","volume":"23","author":"Deibert","year":"2006","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107626_bb0260","first-page":"G496","article-title":"Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis","volume":"305","author":"Delgado","year":"2013","journal-title":"American Journal of Physiology: Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0265","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.prostaglandins.2017.08.004","article-title":"Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis","volume":"131","author":"Deng","year":"2017","journal-title":"Prostaglandins & Other Lipid Mediators"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107626_bb0270","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1053\/j.gastro.2014.08.031","article-title":"Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis: A Randomized, Controlled Trial","volume":"147","author":"Dhiman","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0275","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jhep.2012.12.012","article-title":"Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats","volume":"58","author":"Di Pascoli","year":"2013","journal-title":"Journal of hepatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0280","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.28686","article-title":"Inhibition of epoxyeicosatrienoic acid production in rats with cirrhosis has beneficial effects on portal hypertension by reducing splanchnic vasodilation","volume":"64","author":"Di Pascoli","year":"2016","journal-title":"Hepatology"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107626_bb0285","first-page":"2063","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"New England Journal of Medicine. Edited by D. L. Longo. Massachussetts Medical Society"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0290","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"Journal of Hepatology. Elsevier B.V"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107626_bb0295","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/smll.201402870","article-title":"The Use of Nanoparticles to Deliver Nitric Oxide to Hepatic Stellate Cells for Treating Liver Fibrosis and Portal Hypertension","volume":"11","author":"Duong","year":"2015","journal-title":"Small"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107626_bb0300","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00109-018-1642-9","article-title":"Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation","volume":"96","author":"Eguchi","year":"2018","journal-title":"Journal of Molecular Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0305","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/gast.2001.20892","article-title":"Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension","volume":"120","author":"Escorsell","year":"2001","journal-title":"Gastroenterology. W.B. Saunders"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0310","first-page":"G27","article-title":"Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease","volume":"297","author":"Feng","year":"2009","journal-title":"AJP: Gastrointestinal and Liver Physiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0315","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2005.02.022","article-title":"Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats","volume":"43","author":"Fernandez","year":"2005","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0320","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","article-title":"Angiogenesis in liver disease","author":"Fern\u00e1ndez","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0325","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.gastro.2003.12.012","article-title":"Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice","volume":"126","author":"Fernandez","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0330","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fmed.2017.00007","article-title":"How to face chronic liver disease: the sinusoidal perspective","volume":"4","author":"Fern\u00e1ndez-Iglesias","year":"2017","journal-title":"Frontiers in Medicine"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0335","series-title":"The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes","author":"Forlani","year":"2016"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0340","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1517\/14656560903207019","article-title":"Vapreotide: A somatostatin analog for the treatment of acute variceal bleeding","author":"Fortune","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0345","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0350","first-page":"908","article-title":"Mechanisms of NAFLD development and therapeutic strategies","author":"Friedman","year":"2018","journal-title":"Nature Medicine. Nature Publishing Group"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0355","first-page":"1754","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology. John Wiley and Sons Inc."},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0360","first-page":"1304","article-title":"Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man","volume":"73","author":"Frohman","year":"1984","journal-title":"Journal of Clinical Investigation. American Society for Clinical Investigation"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107626_bb0365","article-title":"Loss of Glp2r signaling activates hepatic stellate cells and exacerbates diet-induced steatohepatitis in mice","volume":"5","author":"Fuchs","year":"2020","journal-title":"JCI Insight. American Society for Clinical Investigation"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0370","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jgh.12360","article-title":"Effects of fasudil on the portal and systemic hemodynamics of patients with cirrhosis","volume":"29","author":"Fukuda","year":"2014","journal-title":"Journal of Gastroenterology and Hepatology (Australia). Blackwell Publishing"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107626_bb0375","doi-asserted-by":"crossref","first-page":"e69309","DOI":"10.1371\/journal.pone.0069309","article-title":"Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis","volume":"8","author":"Gao","year":"2013","journal-title":"PloS One. Edited by A. B. Abdel-Naim"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb0380","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2010.07.034","article-title":"Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats","volume":"54","author":"Garc\u00eda-Calder\u00f3","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0385","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107626_bb0390","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMra0901512","article-title":"Management of varices and variceal hemorrhage in cirrhosis","volume":"362","author":"Garcia-Tsao","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0395","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","article-title":"Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension","volume":"72","author":"Garcia-Tsao","year":"2020","journal-title":"Journal of Hepatology. Elsevier B.V"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0400","article-title":"Emricasan (IDN-6556) Lowers Portal Pressure in Patients with Compensated Cirrhosis and Severe Portal Hypertension","author":"Garcia-Tsao","year":"2018","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0405","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003495-199549030-00009","article-title":"Rifaximin: A Review of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Potential in Conditions Mediated by Gastrointestinal Bacteria","volume":"49","author":"Gillis","year":"1995","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107626_bb0410","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/cld.604","article-title":"Mechanisms of portal hypertension: Bench to bedside","volume":"8","author":"Gracia-Sancho","year":"2016","journal-title":"Clinical Liver Disease. Wiley-Blackwell"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0415","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1053\/j.gastro.2007.06.021","article-title":"Evidence Against a Role for NADPH Oxidase Modulating Hepatic Vascular Tone in Cirrhosis","volume":"133","author":"Gracia-Sancho","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0420","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jhep.2007.03.014","article-title":"Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers","volume":"47","author":"Gracia-Sancho","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0425","series-title":"Emricasan ameliorates portal hypertension and liver fibrosis in cirrhotic rats through a hepatocyte-mediated paracrine mechanism","author":"Gracia-Sancho","year":"2019"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0430","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41575-018-0097-3","article-title":"Hepatic microcirculation and mechanisms of portal hypertension","volume":"16","author":"Gracia-Sancho","year":"2019","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb0435","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/gut.2010.220913","article-title":"Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver","volume":"60","author":"Gracia-Sancho","year":"2011","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0440","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.27117","article-title":"Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis","volume":"60","author":"Granzow","year":"2014","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"10152","key":"10.1016\/j.pharmthera.2020.107626_bb0445","first-page":"1015","article-title":"Alcohol use and burden for 195 countries and territories, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"392","author":"Griswold","year":"2018","journal-title":"The Lancet. Lancet Publishing Group"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0450","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jhep.2012.09.010","article-title":"Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats","volume":"58","author":"Guillaume","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107626_bb0455","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/liv.12172","article-title":"Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: A randomized trial","volume":"33","author":"Gupta","year":"2013","journal-title":"Liver International"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0460","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0465","series-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","author":"Harrison","year":"2020"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0470","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ajg.2011.456","article-title":"Development of ascites in compensated cirrhosis with severe portal hypertension treated with \u03b2-blockers","volume":"107","author":"Hern\u00e1ndez-Gea","year":"2012","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0475","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/hep.21080","article-title":"Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension","volume":"43","author":"Hern\u00e1ndez-Guerra","year":"2006","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb0480","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/00365521.2012.666673","article-title":"Carvedilol or propranolol in portal hypertension? A randomized comparison","volume":"47","author":"Hobolth","year":"2012","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107626_bb0485","first-page":"2391","article-title":"Insulin reverses major portal hypertension-related derangements in rats with liver cirrhosis and diabetes","volume":"132","author":"Hsin","year":"2018","journal-title":"Clinical Science. Portland Press Ltd"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107626_bb0490","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1440-1746.2009.06159.x","article-title":"Simvastatin effects on portal-systemic collaterals of portal hypertensive rats","volume":"25","author":"Huang","year":"2010","journal-title":"Journal of Gastroenterology and Hepatology (Australia). Blackwell Publishing"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0495","first-page":"278","article-title":"The Effects of Metformin on Age-Related Changes in the Liver Sinusoidal Endothelial Cell","volume":"75","author":"Hunt","year":"2020","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107626_bb0500","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/gutjnl-2016-312473","article-title":"Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal","volume":"66","author":"Ikenaga","year":"2017","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107626_bb0505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111864","article-title":"A Novel Modular Bioreactor to In Vitro Study the Hepatic Sinusoid","volume":"9","author":"Illa","year":"2014","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb0510","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1053\/jhep.2002.0350964","article-title":"Inflammation in response to hepatocellular apoptosis","volume":"35","author":"Jaeschke","year":"2002","journal-title":"Hepatology (Baltimore, Md.) Hepatology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107626_bb0515","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/liv.12280","article-title":"VSL#3\u00ae probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis","volume":"33","author":"Jayakumar","year":"2013","journal-title":"Liver International"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107626_bb0520","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/apt.14275","article-title":"Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy","volume":"46","author":"Kang","year":"2017","journal-title":"Alimentary Pharmacology and Therapeutics. Blackwell Publishing Ltd"},{"issue":"25","key":"10.1016\/j.pharmthera.2020.107626_bb0525","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"World Journal of Gastroenterology. WJG Press"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0530","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cld.788","article-title":"Patients With Chronic Liver Disease\/Cirrhosis Should Not Take Statin Medications","author":"Kasia","year":"2019","journal-title":"Clinical Liver Disease. John Wiley and Sons Inc"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0535","first-page":"592","article-title":"Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial","volume":"65","author":"Kimer","year":"2017","journal-title":"Hepatology. John Wiley and Sons Inc."},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0540","article-title":"Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats","volume":"9","author":"Klein","year":"2019","journal-title":"Scientific Reports. Nature Publishing Group"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107626_bb0545","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jhep.2012.07.033","article-title":"HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects","volume":"57","author":"Klein","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb0550","first-page":"1270","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology. John Wiley and Sons Inc."},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107626_bb0555","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s10620-014-3179-2","article-title":"Statin use in patients with cirrhosis: A retrospective cohort study","volume":"59","author":"Kumar","year":"2014","journal-title":"Digestive Diseases and Sciences. Springer New York LLC"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0560","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1053\/j.gastro.2006.12.041","article-title":"Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats","volume":"132","author":"Laleman","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0565","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00228-011-1157-6","article-title":"Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis","volume":"68","author":"Lebrec","year":"2012","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"8187","key":"10.1016\/j.pharmthera.2020.107626_bb0570","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0140-6736(80)90063-X","article-title":"Propranolol--a medical treatment for portal hypertension?","volume":"2","author":"Lebrec","year":"1980","journal-title":"Lancet (London, England)"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107626_bb0575","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJM198112033052302","article-title":"Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis: A Controlled Study","volume":"305","author":"Lebrec","year":"1981","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107626_bb0580","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1872-034X.2008.00388.x","article-title":"Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid resistance in cirrhotic patients","volume":"38","author":"Lee","year":"2008","journal-title":"Hepatology Research"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0585","first-page":"13","article-title":"Anticoagulation in cirrhosis: a new paradigm?","author":"Leonardi","year":"2017","journal-title":"Clinical and Molecular Hepatology. Korean Association for the Study of the Liver, pp."},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0590","doi-asserted-by":"crossref","first-page":"e010902","DOI":"10.1136\/bmjopen-2015-010902","article-title":"Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis","volume":"6","author":"Li","year":"2016","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0595","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/jgh.12480","article-title":"Beneficial effects of dual vascular endothelial growth factor receptor\/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats","volume":"29","author":"Lin","year":"2014","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0600","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/hep.22358","article-title":"Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding","volume":"48","author":"Lo","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0605","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0610","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1023\/A:1005553914878","article-title":"48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: Double- blind, placebo-controlled study","volume":"45","author":"Ludwig","year":"2000","journal-title":"Digestive Diseases and Sciences"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107626_bb0615","first-page":"1062","article-title":"New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease","volume":"8","author":"Maeso-D\u00edaz","year":"2019","journal-title":"Cells. MDPI AG"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb0620","doi-asserted-by":"crossref","first-page":"684","DOI":"10.14336\/AD.2019.0127","article-title":"Aging influences hepatic microvascular biology and liver fibrosis in advanced chronic liver disease","volume":"10","author":"Maeso-D\u00edaz","year":"2019","journal-title":"Aging and Disease. International Society on Aging and Disease"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107626_bb0625","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1172\/JCI59261","article-title":"Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration","volume":"121","author":"Malato","year":"2011","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0630","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jhep.2013.03.032","article-title":"Cannabinoid signaling and liver therapeutics","author":"Mallat","year":"2013","journal-title":"Journal of Hepatology. Elsevier B.V"},{"issue":"10190","key":"10.1016\/j.pharmthera.2020.107626_bb0635","first-page":"2493","article-title":"Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study","volume":"393","author":"Manthey","year":"2019","journal-title":"The Lancet. Lancet Publishing Group"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107626_bb0640","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0645","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","article-title":"The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins","volume":"58","author":"Marrone","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0650","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2016.04.018","article-title":"Sinusoidal communication in liver fibrosis and regeneration","volume":"65","author":"Marrone","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0655","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.21228","article-title":"The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis","volume":"44","author":"Matei","year":"2006","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0660","article-title":"Rapid production of human liver scaffolds for functional tissue engineering by high shear stress oscillation-decellularization","volume":"7","author":"Mazza","year":"2017","journal-title":"Scientific Reports. Nature Publishing Group"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb0665","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/gutjnl-2014-307138","article-title":"Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats","volume":"64","author":"Mejias","year":"2015","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0670","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C\u2013Related Compensated Cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107626_bb0675","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0168-8278(01)00206-9","article-title":"Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding","volume":"35","author":"Moitinho","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0680","first-page":"570","article-title":"The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis","author":"M\u00f8ller","year":"2018","journal-title":"Liver International. Blackwell Publishing Ltd"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107626_bb0685","article-title":"Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy","volume":"12","author":"Mullen","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology. W.B. Saunders"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107626_bb0690","first-page":"1795","article-title":"Recent update to the us cholesterol treatment guidelines: A comparison with international guidelines","volume":"133","author":"Nayor","year":"2016","journal-title":"Circulation. Lippincott Williams and Wilkins"},{"issue":"9972","key":"10.1016\/j.pharmthera.2020.107626_bb0695","first-page":"956","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"The Lancet. Lancet Publishing Group"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.04.011","article-title":"Animal Models for Liver Disease - A Practical Approach for Translational Research","author":"Nevzorova","year":"2020","journal-title":"Journal of Hepatology. Elsevier BV"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0705","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12876-019-1155-1","article-title":"Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation","volume":"20","author":"Ngwa","year":"2020","journal-title":"BMC Gastroenterology. BioMed Central Ltd"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0710","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jhep.2015.10.020","article-title":"Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis","volume":"64","author":"Or\u00f3","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107626_bb0715","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1002\/bit.26776","article-title":"Resemblance of the human liver sinusoid in a fluidic device with biomedical and pharmaceutical applications","volume":"115","author":"Ortega-Ribera","year":"2018","journal-title":"Biotechnology and Bioengineering"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0720","first-page":"97","article-title":"Therapies in non-alcoholic steatohepatitis (NASH)","author":"Oseini","year":"2017","journal-title":"Liver International. Blackwell Publishing Ltd"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0725","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31173","article-title":"Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of Nonalcoholic Fatty Liver Disease","author":"Paik","year":"2020","journal-title":"Hepatology. Wiley"},{"issue":"29","key":"10.1016\/j.pharmthera.2020.107626_bb0730","doi-asserted-by":"crossref","first-page":"26714","DOI":"10.1074\/jbc.C500144200","article-title":"Statins exert endothelial atheroprotective effects via the KLF2 transcription factor","volume":"280","author":"Parmar","year":"2005","journal-title":"The Journal of biological chemistry"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107626_bb0735","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJM198710013171403","article-title":"Propranolol in the Prevention of First Upper Gastrointestinal Tract Hemorrhage in Patients with Cirrhosis of the Liver and Esophageal Varices","volume":"317","author":"Pascal","year":"1987","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0740","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jhep.2013.06.017","article-title":"Hepatic ischemia and reperfusion injury: effects on the liver sinusoidal milieu","volume":"59","author":"Peralta","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"8755","key":"10.1016\/j.pharmthera.2020.107626_bb0745","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/0140-6736(91)93125-S","article-title":"Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis","volume":"337","author":"P\u00e9rez-Ayuso","year":"1991","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0750","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jhep.2018.05.011","article-title":"Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies","volume":"69","author":"Pimpin","year":"2018","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0755","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2036.2011.04896.x","article-title":"The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study","volume":"35","author":"Pinter","year":"2012","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb0760","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-2007-1007128","article-title":"Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis","volume":"19","author":"Pinzani","year":"1999","journal-title":"Seminars in Liver Disease"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107626_bb0765","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Digestive and Liver Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0770","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"The Lancet Gastroenterology and Hepatology. Elsevier Ltd"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107626_bb0775","first-page":"930","article-title":"An HNF1\u03b1-regulated feedback circuit modulates hepatic fibrogenesis via the crosstalk between hepatocytes and hepatic stellate cells","volume":"25","author":"Qian","year":"2015","journal-title":"Cell Research. Nature Publishing Group"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0780","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2009.06.024","article-title":"Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats","volume":"51","author":"Reiberger","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107626_bb0785","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol","volume":"62","author":"Reiberger","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0790","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJM198312153092406","article-title":"Somatostatin","author":"Reichlin","year":"1983","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0795","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2036.2003.01657.x","article-title":"Pharmacological rationale for the use of somatostatin and analogues in portal hypertension","author":"Reynaert","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107626_bb0800","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1111\/liv.12539","article-title":"Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites","volume":"34","author":"Rinc\u00f3n","year":"2014","journal-title":"Liver International"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0805","doi-asserted-by":"crossref","first-page":"100063","DOI":"10.1016\/j.jhepr.2019.12.001","article-title":"Beta-blockers in cirrhosis: Evidence-based indications and limitations","volume":"2","author":"Rodrigues","year":"2020","journal-title":"JHEP Reports. Elsevier BV"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb0810","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/hep.26520","article-title":"Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats","volume":"58","author":"Rosado","year":"2013","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0815","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","article-title":"Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians","volume":"340","author":"Rzouq","year":"2010","journal-title":"American Journal of the Medical Sciences. Lippincott Williams and Wilkins"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0820","doi-asserted-by":"crossref","first-page":"9372","DOI":"10.1038\/s41598-018-27656-y","article-title":"The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats","volume":"8","author":"Schwabl","year":"2018","journal-title":"Scientific Reports"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0825","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.104.525774","article-title":"Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells","volume":"112","author":"Sen-Banerjee","year":"2005","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107626_bb0830","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1478-3231.2009.02038.x","article-title":"\u03b2-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: A meta-analysis","volume":"29","author":"Senzolo","year":"2009","journal-title":"Liver International"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0835","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1038\/ajg.2009.457","article-title":"Oral propranolol decreases intestinal permeability in patients with cirrhosis: Another protective mechanism against bleeding","author":"Senzolo","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0840","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Sepanlou","year":"2020","journal-title":"The Lancet Gastroenterology and Hepatology. Elsevier Ltd"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0845","first-page":"130","article-title":"Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation","volume":"847","author":"Sever","year":"2019","journal-title":"European Journal of Pharmacology. Elsevier B.V"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0850","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/apt.12634","article-title":"Systematic review with meta-analysis: The haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis","author":"Sinagra","year":"2014","journal-title":"Alimentary Pharmacology and Therapeutics. Blackwell Publishing Ltd"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107626_bb0855","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/hep.23596","article-title":"Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis","volume":"51","author":"Steib","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0860","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jhep.2016.06.018","article-title":"Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide","volume":"65","author":"Stein","year":"2016","journal-title":"Journal of Hepatology. Elsevier B.V"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0865","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jhep.2010.03.013","article-title":"Renin\u2013angiotensin\u2013aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis","volume":"53","author":"Tandon","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107626_bb0870","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/j.1478-3231.2009.02020.x","article-title":"Effects of probiotic therapy on portal pressure in patients with cirrhosis: A pilot study","volume":"29","author":"Tandon","year":"2009","journal-title":"Liver International"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0875","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb0880","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","article-title":"Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells","volume":"53","author":"Trebicka","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107626_bb0885","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/gut.2005.077453","article-title":"Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: A randomised controlled trial","volume":"55","author":"Tripathi","year":"2006","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0890","doi-asserted-by":"crossref","first-page":"G301","DOI":"10.1152\/ajpgi.00010.2015","article-title":"Metformin reduces hepatic resistance and portal pressure in cirrhotic rats","volume":"309","author":"Tripathi","year":"2015","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0895","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2018.07.022","article-title":"Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension","volume":"155","author":"Tripathi","year":"2018","journal-title":"Gastroenterology. W.B Saunders"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0900","first-page":"147","article-title":"The coagulopathy of chronic liver disease","author":"Tripodi","year":"2011","journal-title":"New England Journal of Medicine. Massachussetts Medical Society"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107626_bb0905","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1053\/j.gastro.2009.08.045","article-title":"An Imbalance of Pro- vs Anti-Coagulation Factors in Plasma From Patients With Cirrhosis","volume":"137","author":"Tripodi","year":"2009","journal-title":"Gastroenterology. W.B Saunders"},{"issue":"9930","key":"10.1016\/j.pharmthera.2020.107626_bb0910","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis","year":"2014","journal-title":"The Lancet. Elsevier Ltd"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0915","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"Journal of Hepatology. Elsevier B.V"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0920","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cld.2019.07.007","article-title":"Portal Hypertension: Pathogenesis and Diagnosis","author":"Turco","year":"2019","journal-title":"Clinics in Liver Disease. W.B. Saunders"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0925","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cgh.2019.05.050","article-title":"Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis","volume":"18","author":"Turco","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology. W.B. Saunders"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb0930","first-page":"G298","article-title":"Mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis in cirrhotic rats","volume":"318","author":"Turkseven","year":"2020","journal-title":"American Journal of Physiology. NLM (Medline)"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0935","first-page":"1466","article-title":"Treatment of Bleeding Esophageal Varices with Somatostatin","author":"Tyd\u00e9n","year":"1978","journal-title":"New England Journal of Medicine. Massachusetts Medical Society"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107626_bb0950","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107626_bb0955","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells","volume":"65","author":"Vilaseca","year":"2017","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107626_bb0960","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/liv.13436","article-title":"Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats","volume":"37","author":"Vilaseca","year":"2017","journal-title":"Liver International"},{"key":"10.1016\/j.pharmthera.2020.107626_bb0965","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818811294","article-title":"Advances in therapeutic options for portal hypertension","volume":"11","author":"Vilaseca","year":"2018","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb0970","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"issue":"10181","key":"10.1016\/j.pharmthera.2020.107626_bb0975","first-page":"1597","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"The Lancet. Lancet Publishing Group"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb0980","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/gast.2001.25536","article-title":"Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding","volume":"121","author":"Villanueva","year":"2001","journal-title":"Gastroenterology. W.B. Saunders"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107626_bb0985","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1365-2036.2009.03958.x","article-title":"Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis","volume":"29","author":"Vlachogiannakos","year":"2009","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb0990","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jgh.12070","article-title":"Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis","volume":"28","author":"Vlachogiannakos","year":"2013","journal-title":"Journal of Gastroenterology and Hepatology (Australia). Blackwell Publishing"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107626_bb0995","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/j.1572-0241.2007.01390.x","article-title":"Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: A randomized, controlled trial","volume":"102","author":"Vorobioff","year":"2007","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb1000","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1053\/gast.2002.32395","article-title":"Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: A randomized, controlled trial","volume":"122","author":"Vorobioff","year":"2002","journal-title":"Gastroenterology. Elsevier"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb1005","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/jgh.13207","article-title":"Combined administration of propranolol+AG490 offers better effects on portal hypertensive rats with cirrhosis","volume":"31","author":"Wang","year":"2016","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb1010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.dld.2014.12.017","article-title":"Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats","volume":"47","author":"Wang","year":"2015","journal-title":"Digestive and Liver Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107626_bb1015","doi-asserted-by":"crossref","first-page":"e83908","DOI":"10.1371\/journal.pone.0083908","article-title":"Rapamycin Ameliorates Inflammation and Fibrosis in the Early Phase of Cirrhotic Portal Hypertension in Rats through Inhibition of mTORC1 but Not mTORC2","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS ONE. Edited by M. A. Avila"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107626_bb1020","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00535-007-2093-1","article-title":"An endothelin A receptor antagonist induces dilatation of sinusoidal endothelial fenestrae: Implications for endothelin-1 in hepatic microcirculation","volume":"42","author":"Watanabe","year":"2007","journal-title":"Journal of Gastroenterology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107626_bb1025","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3892\/ijmm.2014.1905","article-title":"Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA\/Rho-kinase signaling pathway: a preliminary study","volume":"34","author":"Wei","year":"2014","journal-title":"International Journal of Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2020.107626_bb1030","series-title":"Global status report on alcohol and health 2018","author":"WHO","year":"2018"},{"key":"10.1016\/j.pharmthera.2020.107626_bb1035","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","article-title":"Targeting the gut-liver axis in liver disease","author":"Wiest","year":"2017","journal-title":"Journal of Hepatology. Elsevier B.V"},{"key":"10.1016\/j.pharmthera.2020.107626_bb1040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.20632","article-title":"Bacterial translocation (BT) in cirrhosis","author":"Wiest","year":"2005","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb1045","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/liv.12299","article-title":"Anti-VEGFR agents ameliorate hepatic venous dysregulation\/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat","volume":"34","author":"Yang","year":"2014","journal-title":"Liver International"},{"key":"10.1016\/j.pharmthera.2020.107626_bb1050","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11845-018-1765-6","article-title":"Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials","author":"Yao","year":"2018","journal-title":"Irish Journal of Medical Science. Springer London"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107626_bb1055","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"Journal of Hepatology. Elsevier B.V"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb1060","first-page":"564","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut. BMJ Publishing Group"},{"key":"10.1016\/j.pharmthera.2020.107626_bb1065","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nrgastro.2017.72","article-title":"The gut microbiome and liver cancer: Mechanisms and clinical translation","author":"Yu","year":"2017","journal-title":"Nature Reviews Gastroenterology and Hepatology. Nature Publishing Group"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb1070","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/gut.2008.174904","article-title":"Hepatocyte nuclear factor 4\u03b1 attenuates hepatic fibrosis in rats","volume":"59","author":"Yue","year":"2010","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107626_bb1075","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin Enhances Hepatic Nitric Oxide Production and Decreases the Hepatic Vascular Tone in Patients with Cirrhosis","volume":"126","author":"Zafra","year":"2004","journal-title":"Gastroenterology. W.B. Saunders"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107626_bb1080","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.3748\/wjg.v22.i18.4484","article-title":"Role of estrogen receptor \u03b2 selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis","volume":"22","author":"Zhang","year":"2016","journal-title":"World Journal of Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb1085","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.clinre.2017.09.001","article-title":"Soluble epoxide hydrolase inhibition with t-TUCB alleviates liver fibrosis and portal pressure in carbon tetrachloride-induced cirrhosis in rats","volume":"42","author":"Zhang","year":"2018","journal-title":"Clinics and Research in Hepatology and Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107626_bb1090","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"Journal of Hepatology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582030156X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582030156X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:06:52Z","timestamp":1759010812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372582030156X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":216,"alternative-id":["S016372582030156X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107626","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutics for portal hypertension and fibrosis in chronic liver disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107626","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107626"}}